Congress have introduce legislation that would give consumers access to lower cost copies and would authorize the FDA to approve safe lower cost version of biotechnology drugs without the full range of tests normally required for a new product. Who are the stakeholders who will be affected by such legislation? what arguments can you make for or against it?